The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | MOR208: an effective drug for the treatment of CLL
Wojciech Jurczak, MD, PhD, from Jagiellonian University, Krakow, Poland, discusses the potential of administering single-agent MOR208, an anti-CD19 antibody, to treat chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (BCL). Here, he explains that the MOR208 has proven to be very effective in treating CLL but less effective in BCL, although it does overall represent a good candidate for combination therapy, possibly with an anti-PD1 agent. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
